Key Takeaways From IMS Real-World Data on Managing Step-Up Dosing in Relapsed/Refractory Multiple Myeloma

The feasibility and safety of administering bispecific antibodies for multiple myeloma in an outpatient setting are increasingly supported by emerging data. To successfully implement this treatment approach, partnering with practices that have already adopted outpatient administration can provide valuable insights and practical road maps. As bispecific antibodies gain approval for earlier lines of therapy, including newly diagnosed and relapsed myeloma, incorporating outpatient dosing becomes crucial. This shift reflects an unprecedented off-the-shelf treatment paradigm that has the potential to transform multiple myeloma care across all stages of the disease.

Operationalizing outpatient dosing requires careful planning and education. One useful strategy involves prescribing “pocket dexamethasone” for patients to manage early symptoms such as mild fevers or low-grade cytokine release syndrome episodes while en route to a medical facility. This approach can improve safety and allow some adverse events to be managed effectively in the outpatient setting. It is also advisable for centers new to this treatment to start by administering subsequent maintenance doses in outpatient settings, gaining experience before progressing to earlier steps. Established centers should focus on refining their processes to ensure consistent and safe delivery.

Ultimately, outpatient bispecific antibody treatment demands a multidisciplinary effort, robust patient education, and well-defined emergency protocols. As more oncology practices adopt this model, it is vital to maintain clear communication between patients, providers, and emergency care teams. With these measures in place, outpatient dosing can be safely expanded, improving patient convenience without compromising treatment efficacy. The growing availability and success of this approach signal a promising advancement in multiple myeloma management, underscoring the importance of early adoption and collaboration within the oncology community.